%0 Journal Article
%T ERRATUM: Genetic testing for inherited cardiovascular diseases. A position statement of the Polish Cardiac Society endorsed by Polish Society of Human Genetics and Cardiovascular Patient Communities.
%A Biernacka EK
%A Osadnik T
%A Bilińska ZT
%A Krawczyński M
%A Latos-Bieleńska A
%A Łaczmańska I
%A Miszczak-Knecht M
%A Płoski R
%A Ponińska JK
%A Prejbisz A
%A Rubiś P
%A Rudnicka A
%A Szczałuba K
%A Szczygieł JA
%A Własienko P
%A Wołczenko A
%A Zienciuk-Krajka A
%A Ziółkowska L
%A Gil R
%J Kardiol Pol
%V 82
%N 6
%D 2024
%M 38973419
%F 3.71
%R 10.33963/v.phj.101365
%X According to the latest guidelines of European and American medical societies, genetic testing (GT) is essential in cardiovascular diseases for establishing diagnosis, predicting prognosis, enabling initiation of disease-modifying therapy, and preventing sudden cardiac death. The GT result may be relevant for cascade GT in the patient's relatives, for planning his/her profession and physical activity, and for procreative counseling. This position statement has been prepared due to the scarcity of GT in cardiovascular diseases in Poland and the need to expand its availability. We give a concise description of the genetic background of cardiomyopathies, channelopathies, aortopathies, familial hypercholesterolemia, pheochromocytomas, and paragangliomas. The article discusses various aspects of GT in specific populations, such as children or athletes, and also presents prenatal genetic diagnostics. We propose recommendations for GT and counselling, which take into account Polish needs and capabilities. We give an outline of legal regulations, good clinical practice in GT with respect for patient rights, the role of cardiologists and clinical geneticists in GT planning and post-test counseling, and the requirements for laboratories performing genetic tests. The Polish Cardiac Society and Polish Society of Human Genetics experts speak with one voice with cardiovascular patient communities to underline the need for a law on GT and increasing the availability of GT for cardiovascular patients.